Key Highlights
- Q2 earnings per share reached $1.94, surpassing analyst expectations of $1.84
- Second-quarter revenue totaled $6.3B, exceeding the $6.1B consensus forecast
- Shares plunged 9% in premarket trading following the earnings announcement
- Company forecasts Q3 core revenue expansion of only 2–3%, missing market expectations
- Annual 2026 core revenue growth projected at 3–4%; adjusted EPS guidance increased to $8.45–$8.60
- Life Sciences division delivered its best quarterly performance in years; bioprocessing orders surged mid-teens
Shares of Danaher (DHR) tumbled 9% during premarket hours Tuesday following the release of a third-quarter growth forecast that failed to meet investor expectations, despite the company delivering strong second-quarter financial results that exceeded Wall Street projections.
The company reported adjusted earnings per share of $1.94, surpassing the analyst consensus estimate of $1.84 by ten cents. Second-quarter revenue reached $6.3 billion, exceeding expectations of $6.1 billion and representing a 5.5% year-over-year uptick.
Core revenue expansion registered at 3.0% compared to the prior year. When respiratory testing revenue is excluded from the calculation, that growth metric improves to 4.5%.
The market reaction wasn’t driven by second-quarter performance — rather, it was about forward guidance.
Management projected third-quarter core revenue growth in the 2–3% range, a forecast that came in below what the Street had anticipated. Looking ahead to the full year 2026, the company anticipates core revenue growth of 3–4%.
On the profitability front, Danaher lifted its full-year 2026 adjusted EPS guidance to a range of $8.45–$8.60, up from the previous band of $8.35–$8.55. The updated midpoint of $8.53 narrowly exceeds the Wall Street consensus of $8.50.
Chief Executive Rainer Blair characterized the results as “a better than expected second quarter,” highlighting improved core growth compared to the first quarter and high-single-digit adjusted earnings per share expansion.
Performance Across Business Segments
Life Sciences emerged as the clear winner, delivering 5.5% core revenue growth — the division’s most impressive quarterly showing in several years, according to company leadership. The Biotechnology segment grew 2.5%, while Diagnostics contributed 2.0% growth.
Bioprocessing revenue faced headwinds from customer project timing delays, though Blair emphasized that fundamental order momentum remained robust, with bioprocessing orders climbing mid-teens percentage points during the period.
Operating cash flow for the second quarter totaled $1.5 billion. Free cash flow generation reached $1.3 billion.
Market Reaction Drivers
The conservative third-quarter guidance range appears to be the primary catalyst behind the sharp selloff. Market participants had anticipated stronger growth acceleration, and a 2–3% core growth projection falls short of those elevated expectations.
Headwinds include pricing challenges in China’s diagnostics sector and inconsistent equipment demand patterns. Additionally, quarter-to-quarter revenue timing variability has created choppy results, making the stock particularly vulnerable to guidance disappointments.
Through the current trading session, DHR shares are down 11.78% for the year.
The company maintains a market capitalization of roughly $144.3 billion, with typical daily trading volume averaging approximately 4.6 million shares.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
